Bristol-Myers Squibb Company and uniQure N.V. announced today an agreement that provides Bristol-Myers Squibb with exclusive access to uniQure’s gene therapy technology platform for multiple targets in cardiovascular diseases.

The collaboration includes uniQure’s proprietary gene therapy program for congestive heart failure that is intended to restore the heart’s ability to synthesize S100A1, a calcium sensor and master regulator of heart function, and thereby improve clinical outcomes for patients with reduced ejection fraction.

Under the agreement, Bristol-Myers will make over $100 million in up-front payments, licensing fees and equity investments in exchange for the commercial rights to uniQure’s lead candidate and three more potential therapies.

press release
article in Fierce Biotech
article in BioCentury